What are their limitations
[3] Clinical trials of tirzepatide, including the SURPASS and SURMOUNT programs involving over 10,000 participants, have not demonstrated a signal for increased incidence of thyroid cancer or thyroid nodules compared to placebo or active comparators during treatment periods up to two years
The choice between them should be based on preference, compliance likelihood, and clinical factors rather than price
Edelman: SGLT2 inhibitors (Farxiga, Invokana, Jardiance, Steglatro) and GLP1-RAs (Adlyxin, Byetta/Bydureon, Ozempic, Rybelsus, Trulicity, Victoza) have now become two of the most important classes of medications for type 2 diabetes
When switching providers with an established treatment history, your new clinician will continue your current dose
Los Reyes del Playback (in Spanish)